Literature DB >> 34350558

A survey of pediatric postoperative pain management in Rwanda.

Brigitte Kalala1,2, Daniel Ferguson3, Francoise Nizeyimana1,2, Shefali Thakore3, Jean Paul Myukiyehe1, Theogene Twagirumugabi1, Gaston Nyirigira1, Paulin Banguti1, Jennifer O'Brien3, William McKay4.   

Abstract

Entities:  

Keywords:  Rwanda; pain; pediatric; postoperative

Mesh:

Year:  2021        PMID: 34350558      PMCID: PMC8336667          DOI: 10.1007/s12630-021-02082-3

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   6.713


× No keyword cloud information.
To the Editor, Research in sub-Saharan Africa has described shortages of pediatric anesthesia airway equipment, medications, training, and personnel. Previous work by our group has shown postoperative pain management of adults in Rwanda, a low income country (LIC), to be inadequate but improving.1,2 Here, we report results of an initial study on the impact of these conditions on postoperative pain in children. With approval of the ethics committees of the Universities of Saskatchewan and Rwanda and of the hospitals, we conducted a prospective observational study from July 2019 to December 2019 of postoperative pain management in children aged 3–16 yr in the teaching hospitals in Kigali and Butare. We obtained consent from parents and assent from children in their preferred language. Participants were invited in the preoperative holding area and followed in the recovery room and ward until postoperative day 2, when the validated Faces Pain Scale – Revised3 and the International Pain Outcomes Questionnaire (IPOQ)4 were administered. The latter scale has not been validated in children, but a parent was always present when it was administered by an interviewer. It has been used in LICs.5 There are no similar pediatric studies in LICs from which to calculate a sample size. We planned on approaching 100 participants, but include data obtained when that number was exceeded because of simultaneous research at two hospitals. We assessed all scale data for normality (Shapiro–Wilk test) and none was Gaussian (P < 0.001). We calculated 99% confidence intervals (CI) for categorical questions. We approached 105 patients with their parents, and all agreed to participate: 90 in Kigali and 15 in Butare; 28 female, 77 male; median [interquartile range (IQR)] age, 8 [4-12] yr. They had 81 major surgeries requiring hospital admission and 24 minor day surgeries. By specialty, there were eight otolaryngology, 24 general, 49 orthopedic, 14 plastic, six urology, two neurosurgery, and two others (a bone marrow aspiration and a complex case involving multiple specialties). Twelve had pre-existing pain. The primary outcome, median [IQR] patient’s worst pain score in the first 48 hr after surgery, was 6 [4-8]; range, 2–10. More than half (58/105) had severe pain with a score of 7 or more. Eighty-one were at risk of severe postoperative pain because of pre-existing pain or major surgery. Only 25/105 (24%) patients were assessed for pain by recovery room staff post-surgery, and of these, only 18 were medicated. All were given pain medication on the surgical or pediatric intensive care ward. Drugs used were combinations of paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), and opioids. Overall, paracetamol was used in 90/105 (86%) patients, NSAIDs in 73/105 (70%), and opioids in 43/105 (41%). Seven patients received only paracetamol, 11 only NSAIDs, and one only an opioid. Other results are found in the Table 1.
Table 1

Perioperative patient management details and International Pain Outcomes Questionnaire results

Perioperative management details
Preoperative, n/total N (%; 99% CI)
Discussed postoperative pain28/105 (26%; 16 to 38)
Operating room, n or an/total N (%; 99% CI)
Surgery durationAnestheticOpioidaLA injected into wounda
< 1 hr 12GA 9989/92 (97%; 92 to 102)4/102 (4%; -1 to 9)
1–2 hr 52SA 2
> 2–4 hr 36GA + RA 1
> 4 hr 5SA + RA 1
Sedation 1
Postanesthesia care unit, n/total N (%; 99% CI) or bn

Pain evaluated

25/104

Pain medication

18/103

Time until

administrationb

(24%; 13 to 35)(17%; 8 to 27)< 15 min 16
15–30 min 1
31–60 min 0
> 1 hr 1

Denominators reflect available data

*There was no use of heat or deep breathing

CI = confidence interval; GA = general anesthesia; IPOQ = International Pain Outcomes Questionnaire; IQR = interquartile range; LA = local anesthetic; NSAID = non-steroidal anti-inflammatory drug; RA = regional anesthesia; SA = spinal anesthesia

Perioperative patient management details and International Pain Outcomes Questionnaire results Pain evaluated 25/104 Pain medication 18/103 Time until administrationb Denominators reflect available data *There was no use of heat or deep breathing CI = confidence interval; GA = general anesthesia; IPOQ = International Pain Outcomes Questionnaire; IQR = interquartile range; LA = local anesthetic; NSAID = non-steroidal anti-inflammatory drug; RA = regional anesthesia; SA = spinal anesthesia As we found in our previous adult study, the worst postoperative pain was high in over half the patients, but the median [IQR] score for satisfaction was also high (8 [7-9]). Postoperative pain was apparently expected by participants and accepted as unavoidable. We postulate that patients and parents were more concerned about getting the surgery done than about pain. This is borne out by a study of 1,626 households with a 99% response rate that found that 6.3% of Rwandan children have a potentially treatable surgical condition.6 Healthcare is improving rapidly in Rwanda. We expect that the present study will suggest areas for improvement of traditional postoperative pain measures, and that the IPOQ results may inform some new directions for quality improvement. We plan to repeat the study to measure any improvement after four or five years depending on the COVID-19 pandemic status.
  1 in total

1.  Quality of postoperative pain management in Ethiopia: A prospective longitudinal study.

Authors:  Million Tesfaye Eshete; Petra I Baeumler; Matthias Siebeck; Markos Tesfaye; Abraham Haileamlak; Girma G Michael; Yemane Ayele; Dominik Irnich
Journal:  PLoS One       Date:  2019-05-01       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.